Publications in VIVO

Co-Author Network

Co-Investigator Network

Cameron, Michael Faculty Member

Positions

Associate Scientific Director I, Translational Research Institute, The Scripps Research Institute 2005 -
Assistant Professor of Molecular Therapeutics (Joint Appointment), Molecular Therapeutics, The Scripps Research Institute

Publications

selected publications

academic article
- Chowdhury, S., Chen, Y. T., Fang, X. G., Grant, W., Pocas, J., Cameron, M. D., Ruiz, C., Lin, L., Park, H., Schroter, T., Bannister, T. D., LoGrasso, P. V., et al. Amino acid derived quinazolines as Rock/PKA inhibitors Bioorganic & Medicinal Chemistry Letters 2013 23:1592-1599 DOI:10.1016/j.bmcl.2013.01.109 PMID:23416002
- Khan, P. M., El-Gendy, Bedm, Kumar, N., Garcia-Ordonez, R., Lin, L., Ruiz, C. H., Cameron, M. D., Griffin, P. R., Kamenecka, T. M. Small molecule amides as potent ror-gamma selective modulators Bioorganic & Medicinal Chemistry Letters 2013 23:532-536 DOI:10.1016/j.bmcl.2012.11.025 PMID:23232056
- Jeso, V., Yang, C., Cameron, M. D., Cleveland, J. L., Micalizio, G. C. Synthesis and sar of lehualide b: A marine-derived natural product with potent anti-multiple myeloma activity ACS Chem Biol 2013 DOI:10.1021/cb300582s PMID:23547759
- Jeso, V., Iqbal, S., Hernandez, P., Cameron, M. D., Park, H., Lograsso, P. V., Micalizio, G. C. Synthesis of benzoquinone ansamycin-inspired macrocyclic lactams from shikimic acid Angewandte Chemie - International Edition 2013 DOI:10.1002/anie.201301323 PMID:23554224
- Chen, Z., Cheng, K., Walton, Z., Wang, Y. C., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., Gao, P., Woo, M. S., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 2012 483:613-617 DOI:10.1038/nature10937 PMID:22425996
- Mousseau, G., Clementz, M. A., Bakeman, W. N., Nagarsheth, N., Cameron, M., Shi, J., Baran, P., Fromentin, R., Chomont, N., Valente, S. T. An analog of the natural steroidal alkaloid cortistatin a potently suppresses tat-dependent hiv transcription Cell Host & Microbe 2012 12:97-108 DOI:10.1016/j.chom.2012.05.016
- Li, X. H., Song, X. Y., Kamenecka, T. M., Cameron, M. D. Discovery of a highly selective cyp3a4 inhibitor suitable for reaction phenotyping studies and differentiation of cyp3a4 and cyp3a5 Drug Metabolism and Disposition 2012 40:1803-1809 DOI:10.1124/dmd.112.046144 PMID:22696420
- Jiang, R., Song, X. Y., Bali, P., Smith, A., Bayona, C. R., Lin, L., Cameron, M. D., McDonald, P. H., Kenny, P. J., Kamenecka, T. M. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists Bioorganic & Medicinal Chemistry Letters 2012 22:3890-3894 DOI:10.1016/j.bmcl.2012.04.122
- Benton, C. S., Miller, B. H., Skwerer, S., Suzuki, O., Schultz, L. E., Cameron, M. D., Marron, J. S., Pletcher, M. T., Wiltshire, T. Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains Psychopharmacology 2012 221:297-315 DOI:10.1007/s00213-011-2574-z
- Song, X. Y., Li, X. H., Ruiz, C. H., Yin, Y., Feng, Y. B., Kamenecka, T. M., Cameron, M. D. Imidazopyridines as selective cyp3a4 inhibitors Bioorganic & Medicinal Chemistry Letters 2012 22:1611-1614 DOI:10.1016/j.bmcl.2011.12.125
- Song, X. Y., Li, X. H., Ruiz, C. H., Yin, Y., Feng, Y., Kamenecka, T. M., Cameron, M. D. Imidazopyridines as selective cyp3a4 inhibitors Bioorganic & Medicinal Chemistry Letters 2012 22:1611-1614 DOI:10.1016/j.bmcl.2011.12.125
- Zhou, L. Y., Ghee, S. M., Chan, C., Lin, L., Cameron, M. D., Kenny, P. J., See, R. E. Orexin-1 receptor mediation of cocaine seeking in male and female rats Journal of Pharmacology and Experimental Therapeutics 2012 340:801-809 DOI:10.1124/jpet.111.187567
- Li, X. H., Cameron, M. D. Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis Chemical Research in Toxicology 2012 25:1004-1011 DOI:10.1021/tx2005635
- Solt, L. A., Wang, Y. J., Banerjee, S., Hughes, T., Kojetin, D. J., Lundasen, T., Shin, Y., Liu, J., Cameron, M. D., Noel, R., Yoo, S. H., Takahashi, J. S., et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists Nature 2012 485:62-68 DOI:10.1038/nature11030 PMID:22460951
- Gonzalez-Cabrera, P. J., Cahalan, S. M., Nguyen, N., Sarkisyan, G., Leaf, N. B., Cameron, M. D., Kago, T., Rosen, H. S1p(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis Molecular Pharmacology 2012 81:166-174 DOI:10.1124/mol.111.076109
- Shin, Y., Noel, R., Banerjee, S., Kojetin, D., Song, X. Y., He, Y. J., Lin, L., Cameron, M. D., Burris, T. P., Kamenecka, T. M. Small molecule tertiary amines as agonists of the nuclear hormone receptor rev-erb alpha Bioorganic & Medicinal Chemistry Letters 2012 22:4413-4417 DOI:10.1016/j.bmcl.2012.04.126
- Song, X., He, Y., Koenig, M., Shin, Y., Noel, R., Chen, W., Ling, Y. Y., Feurstein, D., Lin, L., Ruiz, C. H., Cameron, M. D., Duckett, D. R., et al. Synthesis and sar of 2,4-diaminopyrimidines as potent c-jun n-terminal kinase inhibitors MedChemComm 2012 3:238-243 DOI:10.1039/c1md00219h
- Noel, R., Song, X. Y., Shin, Y., Banerjee, S., Kojetin, D., Lin, L., Ruiz, C. H., Cameron, M. D., Burris, T. P., Kamenecka, T. M. Synthesis and sar of tetrahydroisoquinolines as rev-erb alpha agonists Bioorganic & Medicinal Chemistry Letters 2012 22:3739-3742 DOI:10.1016/j.bmcl.2012.04.023
- Choi, J. H., Banks, A. S., Kamenecka, T. M., Busby, S. A., Chalmers, M. J., Kumar, N., Kuruvilla, D. S., Shin, Y. S., He, Y. J., Bruning, J. B., Marciano, D. P., Cameron, M. D., et al. Antidiabetic actions of a non-agonist ppar gamma ligand blocking cdk5-mediated phosphorylation Nature 2011 477:477-481 DOI:10.1038/nature10383 PMID:21892191
- Sessions, E. H., Chowdhury, S., Yin, Y., Pocas, J. R., Grant, W., Schroter, T., Lin, L., Ruiz, C., Cameron, M. D., LoGrasso, P., Bannister, T. D., Feng, Y. B. Discovery and optimization of indole and 7-azaindoles as rho kinase (rock) inhibitors (part-ii) Bioorganic & Medicinal Chemistry Letters 2011 21:7113-7118 DOI:10.1016/j.bmcl.2011.09.084
- Chowdhury, S., Sessions, E. H., Pocas, J. R., Grant, W., Schroter, T., Lin, L., Ruiz, C., Cameron, M. D., Schurer, S., LoGrasso, P., Bannister, T. D., Feng, Y. B. Discovery and optimization of indoles and 7-azaindoles as rho kinase (rock) inhibitors (part-i) Bioorganic & Medicinal Chemistry Letters 2011 21:7107-7112 DOI:10.1016/j.bmcl.2011.09.083
- Busby, S. A., Kumar, N., Kuruvilla, D. S., Istrate, M. A., Conkright, J. J., Wang, Y. J., Kamenecka, T. M., Cameron, M. D., Roush, W. R., Burris, T. P., Griffin, P. R. Identification of a novel non-retinoid pan inverse agonist of the retinoic acid receptors ACS Chemical Biology 2011 6:618-627 DOI:10.1021/cb100396s PMID:21381756
- Kumar, N., Kojetin, D. J., Solt, L. A., Kumar, K. G., Nuhant, P., Duckett, D. R., Cameron, M. D., Butler, A. A., Roush, W. R., Griffin, P. R., Burris, T. P. Identification of sr3335 (ml-176): A synthetic ror alpha selective inverse agonist ACS Chemical Biology 2011 6:218-222 DOI:10.1021/cb1002762 PMID:21090593
- Crocker, C. E., Khan, S., Cameron, M. D., Robertson, H. A., Robertson, G. S., LoGrasso, P. Jnk inhibition protects dopamine neurons and provides behavioral improvement in a rat 6-hydroxydopamine model of parkinson's disease ACS Chemical Neuroscience 2011 2:207-212 DOI:10.1021/cn1001107 PMID:21666838
- Chambers, J. W., Pachori, A., Howard, S., Ganno, M., Hansen, D., Song, X. Y., Kamenecka, T., Duckett, D., Chen, W. M., Ling, Y. Y., Cherry, L., Cameron, M. D. Small molecule c-jun-n-terminal kinase inhibitors protect dopaminergic neurons in a model of parkinson's disease ACS Chemical Neuroscience 2011 2:198-206 DOI:10.1021/cn100109k PMID:21666839
- Fang, X. A., Chen, Y. T., Sessions, E. H., Chowdhury, S., Vojkovsky, T., Yin, Y., Pocas, J. R., Grant, W., Schroter, T., Lin, L., Ruiz, C., Cameron, M. D., et al. Synthesis and biological evaluation of 4-quinazolinones as rho kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2011 21:1844-1848 DOI:10.1016/j.bmcl.2011.01.039
- Song, X. Y., Chen, W. M., Lin, L., Ruiz, C. H., Cameron, M. D., Duckett, D. R., Kamenecka, T. M. Synthesis and sar of 2-phenoxypyridines as novel c-jun n-terminal kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2011 21:7072-7075 DOI:10.1016/j.bmcl.2011.09.090
- Noel, R., Shin, Y., Song, X. Y., He, Y. J., Koenig, M., Chen, W. M., Ling, Y. Y., Lin, L., Ruiz, C. H., LoGrasso, P., Cameron, M. D., Duckett, D. R., et al. Synthesis and sar of 4-(pyrazol-3-yl)-pyridines as novel c-jun n-terminal kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2011 21:2732-2735 DOI:10.1016/j.bmcl.2010.11.104
- He, Y. J., Kamenecka, T. M., Shin, Y. S., Song, X. Y., Jiang, R., Noel, R., Duckett, D., Chen, W. M., Ling, Y. Y., Cameron, M. D., Lin, L., Khan, S., et al. Synthesis and sar of novel quinazolines as potent and brain-penetrant c-jun n-terminal kinase (jnk) inhibitors Bioorganic & Medicinal Chemistry Letters 2011 21:1719-1723 DOI:10.1016/j.bmcl.2011.01.079
- Tarselli, M. A., Raehal, K. M., Brasher, A. K., Streicher, J. M., Groer, C. E., Cameron, M. D., Bohn, L. M., Micalizio, G. C. Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain Nature Chemistry 2011 3:449-453 DOI:10.1038/nchem.1050
- Li, X. H., Kamenecka, T. M., Cameron, M. D. Cytochrome p450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile Drug Metabolism and Disposition 2010 38:1238-1245 DOI:10.1124/dmd.109.030361
- Yin, Y., Cameron, M. D., Lin, L., Khan, S., Schroter, T., Grant, W., Pocas, J., Chen, Y. T., Schurer, S., Pachori, A., LoGrasso, P., Feng, Y. B. Discovery of potent and selective urea-based rock inhibitors and their effects on intraocular pressure in rats ACS Medicinal Chemistry Letters 2010 1:175-179 DOI:10.1021/ml1000382
- Wang, Y. J., Kumar, N., Nuhant, P., Cameron, M. D., Istrate, M. A., Roush, W. R., Griffin, P. R., Burris, T. P. Identification of sr1078, a synthetic agonist for the orphan nuclear receptors ror alpha and ror gamma ACS Chemical Biology 2010 5:1029-1034 DOI:10.1021/cb100223d PMID:20735016
- Duckett, D. R., Cameron, M. D. Metabolism considerations for kinase inhibitors in cancer treatment Expert Opinion on Drug Metabolism & Toxicology 2010 6:1175-1193 DOI:10.1517/17425255.2010.506873
- Yang, Q. K., Deng, X. M., Lu, B. W., Cameron, M., Fearns, C., Patricelli, M. P., Yates, J. R., Gray, N. S., Lee, J. D. Pharmacological inhibition of bmk1 suppresses tumor growth through promyelocytic leukemia protein Cancer Cell 2010 18:258-267 DOI:10.1016/j.ccr.2010.08.008
- Brothers, S. P., Saldanha, S. A., Spicer, T. P., Cameron, M., Mercer, B. A., Chase, P., McDonald, P., Wahlestedt, C., Hodder, P. S. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening Molecular Pharmacology 2010 77:46-57 DOI:10.1124/mol.109.058677
- Kamenecka, T., Jiang, R., Song, X. Y., Duckett, D., Chen, W. M., Ling, Y. Y., Habel, J., Laughlin, J. D., Chambers, J., Figuera-Losada, M., Cameron, M. D., Lin, L., et al. Synthesis, biological evaluation, x-ray structure, and pharmacokinetics of aminopyrimidine c-jun-n-terminal kinase (jnk) inhibitors Journal of Medicinal Chemistry 2010 53:419-431 DOI:10.1021/jm901351f
- Fang, X. G., Yin, Y., Chen, Y. T., Yao, L., Wang, B., Cameron, M. D., Lin, L., Khan, S., Ruiz, C., Schroter, T., Grant, W., Weiser, A., et al. Tetrahydroisoquinoline derivatives as highly selective and potent rho kinase inhibitors Journal of Medicinal Chemistry 2010 53:5727-5737 DOI:10.1021/jm100579r
- Sessions, E. H., Smolinski, M., Wang, B., Frackowiak, B., Chowdhury, S., Yin, Y., Chen, Y. T., Ruiz, C., Lin, L., Pocas, J., Schroter, T., Cameron, M. D., et al. The development of benzimidazoles as selective rho kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2010 20:1939-1943 DOI:10.1016/j.bmcl.2010.01.124
- Yin, Y., Lin, L., Ruiz, C., Cameron, M. D., Pocas, J., Grant, W., Schroter, T., Chen, W. M., Duckett, D., Schurer, S., LoGrasso, P., Feng, Y. B. Benzothiazoles as rho-associated kinase (rock-ii) inhibitors Bioorganic & Medicinal Chemistry Letters 2009 19:6686-6690 DOI:10.1016/j.bmcl.2009.09.115
- Li, X. H., Kamenecka, T. M., Cameron, M. D. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: Implications for pulmonary and hepatic toxicities Chemical Research in Toxicology 2009 22:1736-1742 DOI:10.1021/tx900256y
- Li, X. H., He, Y. J., Ruiz, C. H., Koenig, M., Cameron, M. D. Characterization of dasatinib and its structural analogs as cyp3a4 mechanism-based inactivators and the proposed bioactivation pathways Drug Metabolism and Disposition 2009 37:1242-1250 DOI:10.1124/dmd.108.025932
- Sessions, E. H., Yin, Y., Bannister, T. D., Weiser, A., Griffin, E., Pocas, J., Cameron, M. D., Ruiz, C., Lin, L., Schurer, S. C., Schroter, T., LoGrasso, P., et al. Benzimidazole- and benzoxazole-based inhibitors of rho kinase Bioorganic & Medicinal Chemistry Letters 2008 18:6390-6393 DOI:10.1016/j.bmcl.2008.10.095
- Chen, Y. T., Bannister, T. D., Weiser, A., Griffin, E., Lin, L., Ruiz, C., Cameron, M. D., Schurer, S., Duckett, D., Schroter, T., LoGrasso, P., Feng, Y. B. Chroman-3-amides as potent rho kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2008 18:6406-6409 DOI:10.1016/j.bmcl.2008.10.080
- Feng, Y. B., Yin, Y., Weiser, A., Griffin, E., Cameron, M. D., Lin, L., Ruiz, C., Schurer, S. C., Inoue, T., Rao, P. V., Schroter, T., LoGrasso, P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective rho kinase (rock-ii) inhibitors Journal of Medicinal Chemistry 2008 51:6642-6645 DOI:10.1021/jm800986w
- Gonzalez-Cabrera, P. J., Jo, E., Sanna, M. G., Brown, S., Leaf, N., Marsolais, D., Schaeffer, M. T., Chapman, J., Cameron, M., Guerrero, M., Roberts, E., Rosen, H. Full pharmacological efficacy of a novel s1p(1) agonist that does not require s1p-like headgroup interactions Molecular Pharmacology 2008 74:1308-1318 DOI:10.1124/mol.108.049783 PMID:18708635
- Miller, B. H., Schultz, L. E., Gulati, A., Cameron, M. D., Pletcher, M. T. Genetic regulation of behavioral and neuronal responses to fluoxetine Neuropsychopharmacology 2008 33:1312-1322 DOI:10.1038/sj.npp.1301497
- Hollander, J. A., Lu, Q., Cameron, M. D., Kamenecka, T. M., Kenny, P. J. Insular hypocretin transmission regulates nicotine reward Proceedings of the National Academy of Sciences of the United States of America 2008 105:19480-19485 DOI:10.1073/pnas.0808023105
- Madoux, F., Li, X. L., Chase, P., Zastrow, G., Cameron, M. D., Conkright, J. J., Griffin, P. R., Thacher, S., Hodder, P. Potent, selective and cell penetrant inhibitors of sf-1 by functional ultra-high-throughput screening Molecular Pharmacology 2008 73:1776-1784 DOI:10.1124/mol.108.045963
- Cameron, M. D., Wen, B., Roberts, A. G., Atkins, W. M., Campbell, A. P., Nelson, S. D. Cooperative binding of acetaminophen and caffeine within the p450 3a4 active site Chemical Research in Toxicology 2007 20:1434-1441 DOI:10.1021/tx7000702
- Cameron, M. D., Wright, J., Black, C. B., Ye, N. In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles Drug Metabolism and Disposition 2007 35:1894-1902 DOI:10.1124/dmd.107.015875
- Feng, Y. B., Cameron, M. D., Frackowiak, B., Griffin, E., Lin, L., Ruiz, C., Schroter, T., LoGrasso, P. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of rock-ii Bioorganic & Medicinal Chemistry Letters 2007 17:2355-2360 DOI:10.1016/j.bmcl.2006.12.043
- Cameron, M. D., Wen, B., Allen, K. E., Roberts, A. G., Schuman, J. T., Campbell, A. P., Kunze, K. L., Nelson, S. D. Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the cyp3a4 active site: A nmr t-1 paramagnetic relaxation study Biochemistry 2005 44:14143-14151 DOI:10.1021/bi051689t
- Cameron, M. D., Aust, S. D. Cellobiose dehydrogenase - an extracellular fungal flavocytochrome Enzyme and Microbial Technology 2001 28:129-138 DOI:10.1016/s0141-0229(00)00307-0
- Cameron, M. D., Poyer, J. F., Aust, S. D. Identification of free radicals produced during phacoemulsification Journal of Cataract and Refractive Surgery 2001 27:463-470 DOI:10.1016/s0886-3350(00)00643-x
- Stahl, J. D., Cameron, M. D., Haselbach, J., Aust, S. D. Biodegradation of superabsorbent polymers in soil Environmental Science and Pollution Research 2000 7:83-88 DOI:10.1065/espr199912.014
- Cameron, M. D., Post, Z. D., Stahl, J. D., Haselbach, J., Aust, S. D. Cellobiose dehydrogenase-dependent biodegradation of polyacrylate polymers by phanerochaete chrysosporium Environmental Science and Pollution Research 2000 7:130-134
- Cameron, M. D., Timofeevski, S., Aust, S. D. Enzymology of phanerochaete chrysosporium with respect to the degradation of recalcitrant compounds and xenobiotics Applied Microbiology and Biotechnology 2000 54:751-758
- Van Aken, B., Cameron, M. D., Stahl, J. D., Plumat, A., Naveau, H., Aust, S. D., Agathos, S. N. Glutathione-mediated mineralization of c-14-labeled 2-amino-4,6-dinitrotoluene by manganese-dependent peroxidase h5 from the white-rot fungus phanerochaete chrysosporium Applied Microbiology and Biotechnology 2000 54:659-664
- Cameron, M. D., Aust, S. D. Kinetics and reactivity of the flavin and heme cofactors of cellobiose dehydrogenase from phanerochaete chrysosporium Biochemistry 2000 39:13595-13601 DOI:10.1021/bi000862c
- Cameron, M. D., Aust, S. D. Degradation of chemicals by reactive radicals produced by cellobiose dehydrogenase from phanerochaete chrysosporium Archives of Biochemistry and Biophysics 1999 367:115-121 DOI:10.1006/abbi.1999.1257

Research

research overview

Drug Metabolism and Pharmacokinetics (DMPK)

My laboratory works to evaluate the metabolic fate and identify compound liabilities of new chemical compounds. My laboratory collaborates with the medicinal chemistry, biology and pharmacology groups within the translational research group at Scripps Florida and with the NIH's Molecular Library Screening Center Network. We evaluate such factors as chemical and metabolic stability, solubility, oral absorption, pharmacokinetics, tissue distribution, protein binding, and metabolite formation. Data is used to refine molecules to enhance desired properties and eliminate undesirable properties. We also attempt to identify compounds that have the potential for metabolic based toxicities and drug-drug interactions. The laboratory researches methods to better predict compound behavior and metabolic based toxicities.

principal investigator on

Characterization of a novel selective cytochrome p450 3a5 substrate awarded by National Institute of Diabetes and Digestive and Kidney Diseases 2012 - 2014

co-principal investigator on

Discovery of potent and selective neuropeptide y y2 receptor antagonist probes awarded by National Institute on Alcohol Abuse and Alcoholism 2010 - 2014

Background

education and training

B.S., Gonzaga University
Ph.D., Utah State University